$51.92
Insights on Incyte Corporation
Revenue is up for the last 2 quarters, 919.02M → 1.01B (in $), with an average increase of 9.3% per quarter
Netprofit is up for the last 2 quarters, 171.26M → 201.07M (in $), with an average increase of 14.8% per quarter
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 75.5%
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 277.6%
0.04%
Downside
Day's Volatility :1.33%
Upside
1.29%
3.18%
Downside
52 Weeks Volatility :33.63%
Upside
31.45%
Period | Incyte Corporation | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -16.08% | -0.4% | 3.0% |
6 Months | -5.77% | 9.6% | 18.8% |
1 Year | -31.0% | 3.9% | 21.2% |
3 Years | -39.33% | 12.8% | 19.9% |
Market Capitalization | 11.8B |
Book Value | $23.14 |
Earnings Per Share (EPS) | 2.65 |
PE Ratio | 19.75 |
PEG Ratio | 0.69 |
Wall Street Target Price | 75.35 |
Profit Margin | 16.17% |
Operating Margin TTM | 20.03% |
Return On Assets TTM | 6.46% |
Return On Equity TTM | 12.5% |
Revenue TTM | 3.7B |
Revenue Per Share TTM | 16.53 |
Quarterly Revenue Growth YOY | 9.3% |
Gross Profit TTM | 1.6B |
EBITDA | 738.5M |
Diluted Eps TTM | 2.65 |
Quarterly Earnings Growth YOY | 6.32 |
EPS Estimate Current Year | 4.55 |
EPS Estimate Next Year | 5.4 |
EPS Estimate Current Quarter | 1.16 |
EPS Estimate Next Quarter | 0.87 |
What analysts predicted
Upside of 45.13%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 22.5% |
Net Income | 109.5M | ↓ 134.97% |
Net Profit Margin | 5.82% | ↑ 26.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.2B | ↑ 14.71% |
Net Income | 446.9M | ↑ 308.16% |
Net Profit Margin | 20.7% | ↑ 14.88% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 2.7B | ↑ 23.53% |
Net Income | -295.7M | ↓ 166.17% |
Net Profit Margin | -11.09% | ↓ 31.79% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↑ 11.98% |
Net Income | 948.6M | ↓ 420.79% |
Net Profit Margin | 31.76% | ↑ 42.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.4B | ↑ 13.67% |
Net Income | 340.7M | ↓ 64.09% |
Net Profit Margin | 10.04% | ↓ 21.72% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | ↑ 8.87% |
Net Income | 597.6M | ↑ 75.42% |
Net Profit Margin | 16.17% | ↑ 6.13% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 823.3M | ↓ 9.67% |
Net Income | 112.8M | ↓ 30.14% |
Net Profit Margin | 13.7% | ↓ 4.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 926.7M | ↑ 12.56% |
Net Income | 28.5M | ↓ 74.76% |
Net Profit Margin | 3.07% | ↓ 10.63% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 808.7M | ↓ 12.74% |
Net Income | 21.7M | ↓ 23.74% |
Net Profit Margin | 2.68% | ↓ 0.39% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 954.6M | ↑ 18.05% |
Net Income | 203.5M | ↑ 837.88% |
Net Profit Margin | 21.32% | ↑ 18.64% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 919.0M | ↓ 3.73% |
Net Income | 171.3M | ↓ 15.86% |
Net Profit Margin | 18.64% | ↓ 2.68% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.0B | ↑ 10.26% |
Net Income | 201.1M | ↑ 17.41% |
Net Profit Margin | 19.84% | ↑ 1.2% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↑ 14.9% |
Total Liabilities | 719.8M | ↑ 7.12% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.4B | ↑ 29.52% |
Total Liabilities | 828.3M | ↑ 15.08% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.6B | ↑ 3.92% |
Total Liabilities | 949.7M | ↑ 14.64% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 38.54% |
Total Liabilities | 1.2B | ↑ 22.5% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 5.8B | ↑ 18.4% |
Total Liabilities | 1.5B | ↑ 26.43% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 6.8B | ↑ 16.11% |
Total Liabilities | 1.6B | ↑ 8.25% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.5B | ↑ 3.59% |
Total Liabilities | 1.3B | ↑ 4.02% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 5.8B | ↑ 6.0% |
Total Liabilities | 1.5B | ↑ 14.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.8B | ↓ 0.74% |
Total Liabilities | 1.3B | ↓ 9.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.2B | ↑ 7.08% |
Total Liabilities | 1.5B | ↑ 9.93% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↑ 2.9% |
Total Liabilities | 1.5B | ↓ 0.73% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.8B | ↑ 6.17% |
Total Liabilities | 1.6B | ↑ 9.3% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 336.2M | ↓ 461.58% |
Investing Cash Flow | -86.4M | ↓ 75.31% |
Financing Cash Flow | 14.7M | ↓ 97.88% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 710.7M | ↑ 111.36% |
Investing Cash Flow | -87.5M | ↑ 1.19% |
Financing Cash Flow | 45.7M | ↑ 211.87% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.6M | ↓ 117.53% |
Investing Cash Flow | -269.0M | ↑ 207.59% |
Financing Cash Flow | 71.7M | ↑ 56.87% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 749.5M | ↓ 701.52% |
Investing Cash Flow | -207.7M | ↓ 22.79% |
Financing Cash Flow | 6.2M | ↓ 91.39% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 969.9M | ↑ 29.41% |
Investing Cash Flow | -78.5M | ↓ 62.18% |
Financing Cash Flow | -794.0K | ↓ 112.86% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 296.4M | ↑ 70.18% |
Investing Cash Flow | -28.4M | ↑ 127.58% |
Financing Cash Flow | -14.3M | ↓ 190.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 283.7M | ↓ 4.29% |
Investing Cash Flow | -20.9M | ↓ 26.37% |
Financing Cash Flow | -2.5M | ↓ 82.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -105.6M | ↓ 137.23% |
Investing Cash Flow | -28.6M | ↑ 36.57% |
Financing Cash Flow | 4.0M | ↓ 261.65% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 306.5M | ↓ 390.26% |
Investing Cash Flow | -7.4M | ↓ 73.99% |
Financing Cash Flow | 12.9M | ↑ 220.98% |
Sell
Neutral
Buy
Incyte Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Incyte Corporation | -9.67% | -5.77% | -31.0% | -39.33% | -31.15% |
Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Incyte Corporation | 19.75 | 19.75 | 0.69 | 4.55 | 0.13 | 0.06 | NA | 23.14 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Incyte Corporation | Buy | $11.8B | -31.15% | 19.75 | 16.17% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Baker Bros Advisors LP
BlackRock Inc
Vanguard Group Inc
Dodge & Cox
State Street Corporation
Renaissance Technologies Corp
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Organization | Incyte Corporation |
Employees | 2524 |
CEO | Mr. Herve Hoppenot |
Industry | Health Technology |
Republic Services, Inc.
$51.92
-0.82%
Thomson Reuters Corp.
$51.92
-0.82%
Union Pacific Corporation
$51.92
-0.82%
Banco De Chile
$51.92
-0.82%
Silver Trust Etf Ishares
$51.92
-0.82%
Reit Vanguard Etf
$51.92
-0.82%
Celanese Corporation
$51.92
-0.82%
Nvent Electric Plc
$51.92
-0.82%
Invesco S&p 500® Equal Weight Etf
$51.92
-0.82%